



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/12, 15/10, 15/54	A2	(11) International Publication Number: WO 98/23733 (43) International Publication Date: 4 June 1998 (04.06.98)
(21) International Application Number: PCT/US97/21940 (22) International Filing Date: 26 November 1997 (26.11.97) (30) Priority Data: 60/031,496 27 November 1996 (27.11.96) US (71) Applicant: UNIVERSITY OF WASHINGTON [US/US]; Suite 200, 1107 N.E. 45th, Seattle, WA 98105 (US). (72) Inventors: LOEB, Lawrence, A.; 13808 Northeast 36th Place, Bellevue, WA 98005 (US). HOOD, Leroy; 6411 N.E. Windermere Road, Seattle, WA 98105 (US). SUZUKI, Motoshi; Aban Rafure Shiga 7-902, Shiga-cho, Kita-ku, Nogoya 462 (JP). (74) Agents: GAY, David, A. et al.; Campbell & Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: THERMOSTABLE POLYMERASES HAVING ALTERED FIDELITY (57) Abstract <p>The present invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example, the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BV	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China			PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

THERMOSTABLE POLYMERASES HAVING ALTERED FIDELITY

This application claims the benefit of priority of United States Provisional Application serial No. 60/031,496, filed November 27, 1996, the entire contents of which is incorporated herein by reference.

This invention was made with government support under grant number OIG-R35-CA-39903 awarded by the National Institutes of Health and grant number BIR9214821 awarded by the National Science Foundation. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

The present invention relates generally to thermostable polymerases and more specifically to methods for identifying polymerase mutants having desired fidelity.

Every living organism requires genetic material, deoxyribonucleic acid (DNA), to pass a unique collection of characteristics to its offspring. Genes are discrete segments of the DNA and provide the information required to generate a new organism. Even simple organisms, such as bacteria, contain thousands of genes, and the number is many fold greater in complex organisms such as humans. Understanding the complexities of the development and functioning of living organisms requires knowledge of these genes. However, the amount of DNA that can be isolated for study has often been limiting.

A major breakthrough in the study of genes was the development of the polymerase chain reaction (PCR). PCR amplifies genes or portions of genes by making many identical copies, allowing isolation of genes from very tiny amounts of DNA. The motors for PCR are DNA polymerases that copy the DNA of each gene during each round of DNA synthesis. Using oligonucleotides that determine the start and termination of DNA synthesis, a single gene can be replicated into millions of copies.

This process has created a revolution in biotechnology and has been used extensively for the identification of mutant genes that are responsible for or associated with inherited human diseases. It is now possible to identify a mutant gene in a single cell, amplify the gene a million times, and establish the nature of the mutation. One application of identifying a mutant gene is the determination of genetic susceptibility to disease, which can be mapped by gene amplification and DNA sequencing.

DNA polymerases function in cells as the enzymes responsible for the synthesis of DNA. They polymerize deoxyribonucleoside triphosphates in the presence of a metal activator, such as Mg^{2+} , in an order dictated by the DNA template or polynucleotide template that is copied. Even though the template dictates the order of nucleotide subunits that are linked together in the newly synthesized DNA, these enzymes also function to maintain the accuracy of this process. The contribution of DNA polymerases to the fidelity of DNA synthesis is mediated by two mechanisms. First, the geometry of the substrate binding site in DNA polymerases contributes to the selection of the complementary deoxynucleoside triphosphates. Mutations within the substrate binding site on the polymerase can alter the fidelity of DNA synthesis. Second, many DNA polymerases contain a

proof-reading 3'-5' exonuclease that preferentially and immediately excises non-complementary deoxynucleoside triphosphates if they are added during the course of synthesis. As a result, these enzymes copy DNA *in vitro* with a fidelity varying from 5×10^{-4} (1 error per 2000 bases) to 10^{-7} (1 error per 10^7 bases) (Fry and Loeb, Animal Cell DNA Polymerases, pp. 221, CRC Press, Inc., Boca Raton, FL. (1986); Kunkel, T.A., J. Biol. Chem. 267:18251-18254 (1992)).

10 *In vivo*, DNA polymerases participate in a spectrum of DNA synthetic processes including DNA replication, DNA repair, recombination, and gene amplification (Kornberg and Baker, DNA Replication, pp. 929, W.H. Freeman and Co., New York (1992)). During each
15 DNA synthetic process, the DNA template is copied once or at most a few times to produce identical replicas. *In vitro* DNA replication, in contrast, can be repeated many times, for example, during PCR.

 In the initial studies with PCR, the DNA
20 polymerase was added at the start of each round of DNA replication. Subsequently, it was determined that thermostable DNA polymerases could be obtained from bacteria that grow at elevated temperatures, and these enzymes need to be added only once. At the elevated
25 temperatures used during PCR, these enzymes would not denature. As a result, one can carry out repetitive cycles of polymerase chain reactions without adding fresh enzymes at the start of each synthetic addition process. The commercial market for the sale of DNA polymerases
30 from thermostable organisms can be conservatively estimated at 200 million dollars per year. DNA polymerases, particularly thermostable polymerases, are

the key to a large number of techniques in recombinant DNA studies and in medical diagnosis of disease.

Due to the importance of DNA polymerases in biotechnology and medicine, it would be highly advantageous to generate DNA polymerases having desired enzymatic properties such as altered fidelity. However, the ability to predict the effect of introducing an amino acid mutation into the sequence of a protein remains very limited. Even when structural information is available for the protein of interest, it is often very difficult to predict the effect of mutations of specific amino acid residues on the function of that protein. In particular, it is extremely difficult to predict amino acid substitutions that will alter the activity of an enzyme to achieve a desirable change.

Despite the limitations in predicting the effect of introducing amino acid substitutions into proteins, a number of mutant DNA polymerases have been discovered, or have been created by site-specific mutagenesis, and have been used in PCR amplification (Tabor and Richardson, Proc. Natl. Acad. Sci. USA 92:6339-6343 (1995)). Some of these mutant polymerases offer particular advantages with respect to thermostability, processivity, length of the newly synthesized DNA product, or fidelity of DNA synthesis. Those that are more accurate for the most part contain a 3'-5' exonuclease activity that removes misincorporated bases prior to adding the next nucleotide during DNA synthesis. However, the current spectrum of mutant DNA polymerases is quite limited. For the most part, these mutants have been obtained by introducing a single base substitution at a specified site, purifying the enzyme and studying the changes in catalytic activity (Joyce and

Steitz, Annu. Rev. Biochem. 63:777-822 (1994)). These laborious and step-wise procedures have been necessary due to the lack of adequate knowledge to predict the effects of most single amino acid substitutions and due
5 to the lack of rules for predicting the effects of multiple simultaneous substitutions.

Thus, there exists a need for rapid and efficient methods to produce and screen for modified polymerases having desired fidelity in polynucleotide
10 synthesis. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The present invention provides a method for identifying a thermostable polymerase having altered
15 fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example,
20 the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids
25 encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity
30 polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also

provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide and amino acid sequence of *Taq* DNA polymerase I (SEQ ID NOS:1 and 2, respectively).

Figure 2 shows a compilation of amino acid substitutions identified in a screen of *Taq* DNA polymerase I mutants. Panel A shows single mutations, which were identified in the screen of a 9% library, listed under the wild type amino acids. Panel B shows the sequence of multiply substituted mutants identified in the screen of a 9% library. Panel C shows mutations selected from a totally random library of selected amino acids.

Figure 3 shows the spectrum of single base changes generated in a forward mutation assay by *Taq* DNA polymerase I mutant Thr664Arg.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to methods for screening and identifying thermostable polymerases that have altered fidelity of DNA synthesis as well as to the resultant polymerase compositions. As disclosed herein, the invention provides rapid and efficient methods to identify polymerase mutants having altered fidelity. These methods are applicable to the identification of

polymerase mutants having a desired activity such as high fidelity or low fidelity. An advantage of the methods is that they use a population of polymerase mutants to rapidly identify active polymerase mutants having altered fidelity. The identification of low fidelity mutants is useful for introducing mutations into specific genes due to the increased frequency of misincorporation of nucleotides during error-prone PCR amplification. The identification of high fidelity mutants is useful for PCR amplification of genes and for mapping of genetic mutations. The methods of the invention can therefore be advantageously applied to the identification of polymerase mutants useful for the characterization of specific genes and for the identification and diagnosis of human genetic diseases.

As used herein, the term "polymerase" is intended to refer to an enzyme that polymerizes nucleoside triphosphates. Polymerases use a template nucleic acid strand to synthesize a complementary nucleic acid strand. The template strand and synthesized nucleic acid strand can independently be either DNA or RNA. Polymerases can include, for example, DNA polymerases such as *Escherichia coli* DNA polymerase I and *Thermus aquaticus* (Taq) DNA polymerase I, DNA-dependent RNA polymerases and reverse transcriptases. The polymerase is a polypeptide or protein containing sufficient amino acids to carry out a desired enzymatic function of the polymerase. The polymerase need not contain all of the amino acids found in the native enzyme but only those which are sufficient to allow the polymerase to carry out a desired catalytic activity. Catalytic activities include, for example, 5'-3' polymerization, 5'-3' exonuclease and 3'-5' exonuclease activities.

As used herein, the term "polymerase mutant" is intended to refer to a polymerase that contains one or more amino acids that differ from a selected polymerase. The selected polymerase is determined based on desired enzymatic properties and is used as a parent polymerase to generate a population of polymerase mutants. A selected polymerase can be, for example, a wild type polymerase as isolated from an organism or can be a mutant polymerase that differs from a wild type polymerase by one or more amino acids and has desirable enzymatic properties. As disclosed herein, a thermostable polymerase such as *Taq* DNA polymerase I can be selected, for example, as a polymerase to generate a population of polymerase mutants.

As used herein, the term "population" is intended to refer to a group of two or more different molecular species. Molecular species differ by some detectable property such as a difference in at least one amino acid residue or at least one nucleotide residue or a difference introduced by the modification of an amino acid such as the addition of a chemical functional group. For example, a population of polymerase mutants would contain two or more different polymerase mutants. Typically, populations can be as small as two species and as large as 10^{12} species. In some embodiments, populations are between about five and 20 different species as well as up to hundreds or thousands of different species. In other embodiments, populations can be, for example, greater than 10^4 , 10^5 and 10^6 different species. In the specific example presented in Example I, the population described therein is 50,000 different species. In yet other embodiments, populations are between about 10^6 - 10^8 or more different species. Those skilled in the art will know a suitable size and

diversity of a population sufficient for a particular application.

A population of polymerase mutants consists of two or more mutant polymerases which differ by at least one amino acid from the parent polymerase. A population of polymerase mutants can consist, for example, of multiple substitutions of a single amino acid residue where the substitutions are changes to any or all of the non-parental, naturally occurring amino acids at that amino acid position. In this example, the population would comprise nineteen members, and all members of the polymerase mutant population would consist of nineteen different amino acid substitutions at a single amino acid position. A population of polymerase mutants can also consist, for example, of at least one substitution at two or more different amino acid positions. In this example, a minimal population containing two polymerase mutants would consist of a single amino acid substitution at two different positions. Such a population can be expanded with the addition of substitutions to any or all of the 19 non-parental amino acids at these two amino acid positions or additional amino acid positions.

As used herein, the term "random" when used in reference to a population is intended to refer to a population of molecules generated without limiting the molecules to contain predetermined specific residues. Such a population excludes molecules in which a specific residue is substituted with a specific predetermined residue and individually assayed to determine its activity. The residues can be amino acid residues or nucleotide residues encoding a codon. The random molecules can be generated, for example, by introducing random nucleotides into an oligonucleotide sequence that

encodes an amino acid sequence of a protein region of interest (see Example I). Thus, a random population is generated to contain random oligonucleotide sequences which can be expressed in appropriate cells to generate a random population of expressed proteins. A specific example of such a random population is the population of polymerase mutants described in Example I that were generated to screen for active polymerase mutants having altered fidelity.

As used herein, the term "catalytic activity" or "activity" when used in reference to a polymerase is intended to refer to the enzymatic properties of the polymerase. The catalytic activity includes, for example: enzymatic properties such as the rate of synthesis of nucleic acid polymers; the K_m for substrates such as nucleoside triphosphates and template strand; the fidelity of template-directed incorporation of nucleotides, where the frequency of incorporation of non-complementary nucleotides is compared to that of complementary nucleotides; processivity, the number of nucleotides synthesized by a polymerase prior to dissociation from the DNA template; discrimination of the ribose sugar; and stability, for example, at elevated temperatures. Polymerases can discriminate between templates, for example, DNA polymerases generally use DNA templates and RNA polymerases generally use RNA templates, whereas reverse transcriptases use both RNA and DNA templates. DNA polymerases also discriminate between deoxyribonucleoside triphosphates and dideoxyribonucleoside triphosphates. Any of these distinct enzymatic properties can be included in the meaning of the term catalytic activity, including any single property, any combination of properties or all of the properties. Although specific embodiments

identifying polymerase mutants having altered fidelity are exemplified herein, the methods of the invention can similarly be applied to identify polymerases having altered catalytic activity distinct from altered
5 fidelity.

As used herein, the term "fidelity" when used in reference to a polymerase is intended to refer to the accuracy of template-directed incorporation of complementary bases in a synthesized DNA strand relative
10 to the template strand. Fidelity is measured based on the frequency of incorporation of incorrect bases in the newly synthesized nucleic acid strand. The incorporation of incorrect bases can result in point mutations, insertions or deletions. Fidelity can be calculated
15 according to the procedures described in Tindall and Kunkel (Biochemistry 27:6008-6013 (1988)). Methods for determining fidelity are well known in the art and include, for example, those described in Example III. A polymerase or polymerase mutant can exhibit either high
20 fidelity or low fidelity. As used herein, the term "high fidelity" is intended to mean a frequency of accurate base incorporation that exceeds a predetermined value. Similarly, the term "low fidelity" is intended to mean a frequency of accurate base incorporation that is lower
25 than a predetermined value. The predetermined value can be, for example, a desired frequency of accurate base incorporation or the fidelity of a known polymerase.

As used herein, the term "altered fidelity" refers to the fidelity of a polymerase mutant that
30 differs from the fidelity of the selected parent polymerase from which the polymerase mutant is derived. The altered fidelity can either be higher or lower than the fidelity of the selected parent polymerase. Thus,

- polymerase mutants with altered fidelity can be classified as high fidelity polymerases or low fidelity polymerases. Altered fidelity can be determined by assaying the parent and mutant polymerase and comparing their activities using any assay that measures the accuracy of template directed incorporation of complementary bases. Such methods for measuring fidelity include, for example, those described in Example III as well as other methods known to those skilled in the art.
- As used herein, the term "immutable" when used in reference to an amino acid residue is intended to refer to an amino acid residue which cannot be substituted with another amino acid residue and still retain measurable function of the polypeptide. An immutable amino acid residue can be determined by introducing one or more substitutions of an amino acid residue and assaying the resulting mutant polypeptides for polypeptide function. An immutable residue can be identified, for example, using site-directed mutagenesis to substitute each of the 19 non-parental amino acids at a given position and determining if any of these mutants are active. Random mutagenesis can also be employed to introduce substitutions of each of the nineteen, naturally occurring non-parental amino acids at a given position. Random mutagenesis can provide a statistical representation of all 20 amino acids at a given position. Sequencing of polymerase mutants allows determination of whether a given amino acid residue can tolerate any mutations. Assays for determining the function of mutant polypeptides include *in vitro* enzymatic assays as well as genetic complementation assays such as those described in Example I. If substitution of an amino acid residue with any other amino acid results in loss of polypeptide

function, then that amino acid residue is considered to be immutable.

As used herein, the term "nearly immutable" when used in reference to an amino acid residue is intended to refer to an amino acid residue which can only tolerate conservative substitutions and still retain polypeptide function. Conservative amino acids are known to those skilled in the art and include those amino acids which have similar structure and chemical properties. Conservative substitutions of amino acids include, for example, the identification of amino acid substitutions based on the frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz and Schirmer, Principles of Protein Structure, Springer Verlag, New York (1979)).

As used herein, the term "substantially" or "substantially the same" when used in reference to a nucleotide or amino acid sequence is intended to mean that the function of the polypeptide encoded by the nucleotide or amino acid sequence is essentially the same as the referenced parental nucleotide or amino acid sequence. For example, changes in a nucleotide or amino acid sequence that results in substitution of amino acids that differ from the parent molecule but that do not alter the desired activity of the encoded polypeptide would result in substantially the same sequence. A nucleotide or amino acid sequence is substantially the same if the difference in that sequence from the reference parental sequence does not result in any measurable difference in the desired activity of the encoded polypeptide.

The invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection.

The generation and identification of polymerases having altered fidelity or altered catalytic activity is accomplished by first creating a population of mutant polymerases through random sequence mutagenesis of regions within the polymerase that can influence the fidelity of polymerization (Loeb, L.A., Adv. Pharmacol. 35:321-347 (1996)). The identification of active mutants is performed *in vivo* and is based on genetic complementation of conditional polymerase mutants under non-permissive conditions. Once identified, the active polymerases are then screened for fidelity of polynucleotide synthesis.

The methods of the invention employ a population of polymerase mutants and the screening of the polymerase mutant population to identify an active polymerase mutant. Using a population of polymerase mutants is advantageous in that a number of amino acid substitutions including single amino acid and multiple amino acid substitutions can be examined for their effect on polymerase fidelity. The use of a population of polymerase mutants increases the probability of identifying a polymerase mutant having a desired fidelity.

Screening a population of polymerase mutants has the additional advantage of alleviating the need to

make predictions about the effect of specific amino acid substitutions on the activity of the polymerase. The substitution of single amino acids has limited predictability as to its effect on enzymatic activity and the effect of multiple amino acid substitutions is virtually unpredictable. The methods of the invention allow for screening a large number of polymerase mutants which can include single amino acid substitutions and multiple amino acid substitutions. In addition, using screening methods that select for active polymerase mutants has the additional advantage of eliminating inactive mutants that could complicate screening procedures that require purification of polymerase mutants to determine activity.

Moreover, the methods of the invention allow for targeting of amino acid residues adjacent to immutable or nearly immutable amino acid residues. Immutable or nearly immutable amino acid residues are residues required for activity, and those immutable residues located in the active site provide critical residues for polymerase activity. Mutating amino acid residues adjacent to these required residues provides the greatest likelihood of modulating the activity of the polymerase. Introducing random mutations at these sites increases the probability of identifying a mutant polymerase having a desired alteration in activity such as altered fidelity.

A polymerase is selected as a parent polymerase to introduce mutations for generating a library of mutants. Polymerases obtained from thermophilic organisms such as *Thermus aquaticus* have particularly desirable enzymatic characteristics due to their stability and activity at high temperatures. Thermostable polymerases

are stable and retain activity at temperatures greater than about 37°C, generally greater than about 50°C, and particularly greater than about 90°C. The use of the thermostable polymerase *Taq* DNA polymerase I as a parent
5 polymerase to generate polymerase mutants is disclosed herein (see Example I).

Although a specific embodiment using *Taq* DNA polymerase I is disclosed in the examples, the methods of the invention can similarly be applied to other
10 thermostable polymerases other than *Thermus aquaticus* DNA polymerases. Such other polymerases include, for example, RNA polymerases from *Thermus aquaticus* and RNA and DNA polymerases from other thermostable bacteria. Using the guidance provided herein in reference to DNA
15 polymerases, those skilled in the art can apply the teachings of the invention to the generation and identification of these other polymerases having altered fidelity of polynucleotide synthesis.

In addition to creating mutant DNA polymerases
20 from organisms that grow at elevated temperatures, the methods of the invention can similarly be applied to non-thermostable polymerases provided that there is a selection or screen such as the genetic complementation of a conditional polymerase mutation as described herein
25 (see Example I). Such a selection or screen of a non-thermostable polymerase can be, for example, the inducible or repressible expression of an endogenous polymerase. Polymerases having altered fidelity can similarly be generated and selected from both prokaryotic
30 and eukaryotic cells as well as viruses. Those skilled in the art will know how to apply the teachings described herein to the generation of polymerases having altered

fidelity from such other organisms and such other cell types.

Thus, the invention provides a general method for the production of a polymerase that has an altered fidelity in DNA or RNA synthesis. The method consists of producing a population of sufficient size and diversity so as to contain at least one polymerase molecule having an altered fidelity and then screening that population to identify the polymerase having altered fidelity. The altered polymerase fidelity can be either an increase or decrease in the accuracy of DNA synthesis.

In one embodiment, the invention involves the production of a relatively large population of randomly mutagenized nucleic acids encoding a polymerase and introduction of the population into host cells to produce a library. The mutagenized polymerase encoding nucleic acids are expressed, and the library is screened for active polymerase mutants by complementation of a temperature sensitive mutation of an endogenous polymerase. Colonies which are viable at the non-permissive temperature are those which have polymerase encoding nucleic acids which code for active mutants.

To generate a random population of polymerase mutants, a random sequence of nucleotides is substituted for a defined target sequence of a plasmid-encoded gene that specifies a biologically active molecule. In one application of this procedure, a double-stranded oligodeoxyribonucleotide is provided by hybridizing two partially complementary oligonucleotides, one or both of which contain random sequences at specified positions. The partially double-stranded oligonucleotide is filled

in by DNA polymerase, cut at restriction sites and ligated into a DNA vector. The plasmid encodes the gene for a thermostable DNA polymerase, and the oligonucleotide is inserted in place of a portion of the gene that modulates the fidelity of DNA synthesis. After ligation, the reconstructed plasmids constitute a library of different nucleic acid sequences encoding the thermostable DNA polymerase and polymerase mutants.

As disclosed herein, a genetic screen can be used to identify active polymerase mutants having altered fidelity. The library of nucleic acid sequences encoding polymerase and polymerase mutants are transfected into a bacterial strain such as *E. coli* strain *recA718 polA12*, which contains a temperature sensitive mutation in DNA polymerase. Exogenous DNA polymerases have been shown to functionally substitute for *E. coli* DNA polymerase I using *E. coli* strain *recA718 polA12* and to complement the observed growth defect at elevated temperature, presumably caused by the instability of the endogenous DNA polymerase I at elevated temperatures (Sweasy and Loeb, J. Biol. Chem. 267:1407-1410 (1992); Kim and Loeb, Proc. Natl. Acad. Sci USA 92:684-688 (1995)). It was unknown, however, whether a thermostable polymerase could substitute for *E. coli* DNA polymerase given the distinct and harsh environment experienced by thermophilic organisms in which enzymes must function at extremely high temperatures. As disclosed herein, wild type *Taq* DNA polymerase I was found to complement the growth defect of *E. coli* strain *recA718 polA12* (see Example I). Using such a complementation system, various mutant *Taq* DNA polymerase I mutants were identified in host bacteria that harbor plasmids encoding active thermoresistant DNA polymerases that allowed bacterial growth and colony

formation at elevated (restrictive) temperatures (see Examples I and II).

The invention also provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase and screening the population for one or more active polymerase mutants.

10 The invention additionally provides a method for identifying a thermostable polymerase having altered catalytic activity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase
15 and screening the population for one or more active polymerase mutants.

A random population of polymerase mutants is generated by mutating one or more amino acid residues in an active site O-helix target sequence of a thermostable
20 polymerase. The O-helix has been postulated to interact with the substrate template complex (Joyce and Steitz, *supra*, (1994)). The O-helix has been observed in the crystal structure of *E. coli* DNA polymerase I Klenow fragment and *Taq* DNA polymerase (Beese et al., Science
25 260:352-355 (1993); Kim et al., Nature 376:612-616 (1995)). As disclosed in Example II, random sequences were substituted for nucleotides encoding amino acids Arg659 through Tyr671 of the O-helix of *Taq* DNA
30 polymerase I to generate a random population of polymerase mutants.

Using a genetic complementation screen, a variety of active Taq DNA polymerase I mutants were identified (see Example II). Several amino acid residues were found to be immutable or nearly immutable based on the complementation assay. These immutable or nearly immutable amino acid residues in the O-helix are Arg659, Lys663, Phe667 and Tyr671. As used herein, a wild type amino acid is designated as a residue preceding the number of the amino acid position. A mutated amino acid is designated as a residue following the number of the amino acid position. These immutable or nearly immutable sites are unable to be altered and still maintain the function of the DNA polymerase. Due to their position in the active site O-helix of Taq DNA polymerase I, these immutable or nearly immutable residues provide critical residues that are required for the activity of the polymerase.

In addition to the O-helix of a polymerase, other regions of the polymerase can be targeted for random mutagenesis to generate a library of polymerase mutants to identify polymerase mutants having altered fidelity. Those skilled in the art can determine other regions to target for mutagenesis. Such other regions can be identified, for example, by sequence homology to other polymerases, which suggests conservation of function. Conserved sequences can also be used to identify target regions for mutagenesis based on activity studies of other polymerases. Protein structural models revealing the convergence of amino acid residues at the active site of a polymerase can similarly be used to identify target regions for mutagenesis.

Alternatively, mutagenesis throughout the polymerase can be used to identify amino acid residues

critical for polymerase function. Sequences containing these critical amino acid residues are target sequences for introducing random mutations to identify mutants having altered fidelity. Methods for identifying
5 critical amino acid residues by introducing a small number of random mutations throughout a gene segment are well known to those skilled in the art and include, for example, copying by mutagenic polymerases, exposure of templates to DNA damaging agents prior to inserting into
10 cells and replacement of regions of the DNA template with oligonucleotides containing sparsely populated random inserts. For example, a population of oligonucleotides with 91% correct substitutions and 3% of the non-complementary nucleotides at each position can be
15 generated. Screening for polymerase mutants can be performed, for example, with the genetic complementation assay disclosed herein.

The invention also provides a method for identifying a thermostable polymerase having altered
20 fidelity. The method consists of generating a random population of polymerase mutants by mutating one or more amino acid residues adjacent to an immutable or nearly immutable residue in an active site O-helix of a thermostable polymerase and screening the population for
25 one or more active polymerase mutants.

In one embodiment, substitutions at amino acids adjacent to immutable or nearly immutable residues are used to identify polymerase mutants having altered fidelity. The adjacent amino acid residues can be
30 immediately adjacent in the linear sequence or can be nearby. Adjacent residues that are nearby can be as many as two amino acids away from the immutable or nearly immutable residue in the linear sequence. A nearby

residue can also be nearby in the three-dimensional structure of the polymerase and can be determined from a crystallographic molecular model of a polymerase. Nearby residues are in close enough proximity to an immutable or
5 nearly immutable residue to modulate the activity of the polymerase. Generally, nearby residues are within two amino acid residues in the linear sequence from an immutable or nearly immutable residue or are within about 5Å of the immutable or nearly immutable residues, in
10 particular within about 3Å.

Substitutions involving amino acid residues adjacent to immutable or nearly immutable sites have been found to alter the fidelity of DNA synthesis (see Examples IV and V). The identified immutable or nearly
15 immutable amino acid residues correspond to amino acid residues Arg659, Lys663, Phe667 and Tyr671 of *Taq* DNA polymerase I. Thus, the invention is directed to altering one or more amino acid residues adjacent to an amino acid residue corresponding to Arg659, Lys663,
20 Phe667 or Tyr671 in *Taq* DNA polymerase. Amino acid residues adjacent to these immutable residues include, for example, amino acids corresponding to Arg660, Ala661, Ala662, Thr664, Ile665, Asn666, Gly668, Val669 and Leu670 in *Taq* DNA polymerase I. Corresponding residues in other
25 polymerases are also included and can be identified based on sequence homology or based on corresponding amino acids in structurally similar domains as defined by a crystallographic molecular model.

The methods of the invention are also directed
30 to altering residues immediately adjacent to the immutable or nearly immutable residues. Thus, the methods of the invention are directed to altering residues adjacent to required residues on DNA polymerases

and identifying those mutations which have an effect on the fidelity of DNA synthesis.

The invention further provides methods for determining a fidelity of the active polymerase mutant.

- 5 The fidelity of active polymerase mutants can be determined by several methods. The active polymerases can be, for example, screened for altered fidelity from crude extracts of bacterial cells grown from the viable colonies. Methods for determining fidelity of synthesis
10 are disclosed herein (see Example III). In one method, a primer extension assay is used with a biased ratio of nucleoside triphosphates consisting of only three of the nucleoside triphosphates. Elongation of the primer past template positions that are complementary to the deleted
15 nucleoside triphosphate substrate in the reaction mixture results from errors in DNA synthesis. Processivity of high fidelity polymerases will terminate when they encounter a template nucleotide complementary to the missing nucleoside triphosphate whereas the low fidelity
20 polymerases will be more likely to misincorporate a non-complementary nucleotide. The accuracy of incorporation for the primer extension assay can be measured by physical criteria such as by determining the size or the sequence of the extension product. This method is
25 particularly suitable for screening for low fidelity mutants since increases in chain elongation are easily and rapidly quantitated.

- A second method for determining the fidelity of polymerase mutants employs a forward mutation assay. A
30 template containing a single stranded gap in a reporter gene such as *lacZ* is used for the forward mutation assay. Filling in of the gapped segment is carried out by crude heat denatured bacterial extracts harboring plasmids

expressing a thermostable DNA polymerase mutant. For determining low fidelity polymerase mutants, reactions are carried out in the presence of equimolar concentrations of each nucleoside triphosphate. For determining high fidelity polymerase mutants, the reaction is carried out with a biased pool of nucleoside triphosphates. Using a biased pool of nucleoside triphosphates results in incorporation of errors in the synthesized strand that are proportional to the ratio of non-complementary to complementary nucleoside triphosphates in the reaction. Therefore, the bias exaggerates the errors produced by the polymerases and facilitates the identification of high fidelity mutants. The fidelity of DNA synthesis is determined from the number of mutations produced in the reporter gene.

Procedures other than those described above for identifying and characterizing the fidelity of a polymerase are known in the art and can be substituted for identifying high or low fidelity mutants. Those skilled in the art can determine which procedures are appropriate depending on the needs of a particular application.

Also provided herein is an isolated thermostable polymerase mutant having altered fidelity. The polymerase mutant has one or more mutated amino acid residues in the active site O-helix of a thermostable polymerase. Additionally provided is an isolated thermostable polymerase mutant having altered fidelity. The polymerase mutant has one or more mutated amino acid residues adjacent to an immutable or nearly immutable amino acid residue in the active site O-helix of a thermostable polymerase. The mutated amino acid residue

is adjacent to an amino acid residue corresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNA polymerase.

The invention also provides an isolated thermostable polymerase mutant having altered fidelity, where the polymerase has one or more mutated amino acid residues adjacent to an amino acid residue corresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNA polymerase and the mutant is a high fidelity mutant.

Using the methods of the invention, a number of mutants have been identified as having high fidelity of DNA synthesis. For example, polymerases having one or more single-base substitutions adjacent to Arg659, Lys663, Phe667, and Tyr671 in the nucleotide sequence of Taq DNA polymerase I have been identified. Specific examples of these high fidelity mutants include, for example, polymerases having the single substitutions Asn666Asp, Asn666Ile, Ile665Leu, Leu670Val, Arg660Tyr, Arg660Ser, Gly668Arg, Arg660Lys, Gly668Ser and Gly668Gln; polymerases having the double substitutions consisting of Thr664Ile together with Asn666Asp, and Ala661Ser together with Val669Leu; as well as polymerases having the triple substitutions consisting of Thr664Pro, Ile665Val together with Asn666Tyr, and Ala661Glu, Ile665Thr together with Phe667Leu. Additional high fidelity mutants include, for example, Phe667Leu and Phe667Tyr.

The invention provides a high fidelity polymerase mutant having one or more amino acid substitutions selected from the group consisting of Phe667Leu; Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr; Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile and Asn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu; and

Thr664Pro, Ile665Val and Asn666Tyr. The polymerase mutant Phe667Tyr has been previously described and is excluded from the compositions of the invention.

- The invention also provides an isolated
- 5 thermostable polymerase mutant having altered fidelity, where the polymerase has one or more mutated amino acid residues adjacent to an amino acid residue corresponding to Arg659, Lys663, Phe667 or Tyr671 in *Taq* DNA polymerase and the mutant is a low fidelity mutant. The invention
- 10 additionally provides a low fidelity polymerase mutant having one or more amino acid substitutions selected from the group consisting of Ala661Glu; Ala661Pro; Thr664Pro; Thr664Asn; Thr664Arg; Asn666Val; Thr664Pro and Val669Ile; Arg660Pro and Leu670Thr; Arg660Trp and Thr664Lys;
- 15 Ala662Gly and Thr664Asn; Ala661Gly and Asn666Ile; Ala661Pro and Asn666Ile; and Ala661Ser, Ala662Gly, Thr664Ser and Asn666Ile.

- Low fidelity mutant DNA polymerases include mutations involving substitutions at Ala661, Thr664,
- 20 Asn666, and Leu670. Specific examples of low fidelity mutants include, for example, polymerases having the single substitutions Ala661Glu, Ala661Pro, Thr664Pro, Thr664Asn, Thr664Arg and Asn666Val; polymerases having the double substitutions consisting of Thr664Pro together
- 25 with Val669Ile, Arg660Pro together with Leu670Thr, Arg660Trp together with Thr664Lys, Ala664Gly together with Thr664Asn, Ala661Gly together with Asn666Ile, and Ala661Pro together with Asn666Ile; as well as polymerases having four substitutions consisting of Ala661Ser,
- 30 Ala662Gly, Thr664Ser together with Asn666Ile.

For both the high fidelity and the low fidelity mutations described above, the invention provides

polymerases other than *Taq* DNA polymerase having mutations at corresponding positions. In particular, the invention provides thermostable polymerases other than *Taq* DNA polymerase that have mutations at corresponding
5 positions and that have altered fidelity. Those skilled in the art can determine corresponding positions based on sequence homology between the polymerases.

The invention also provides an isolated nucleic acid molecule encoding a polymerase mutant having high
10 fidelity. The nucleic acid molecule contains a nucleotide sequence encoding substantially an amino acid sequence of *Taq* DNA polymerase I having one or more amino acid substitutions selected from the group consisting of Phe667Leu; Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val;
15 Arg660Tyr; Phe667Tyr; Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile and Asn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu; and Thr664Pro, Ile665Val and Asn666Tyr.

Additionally provided is an isolated nucleic
20 acid molecule encoding a polymerase mutant having low fidelity. The nucleic acid molecule contains a nucleotide sequence encoding substantially an amino acid sequence of *Taq* DNA polymerase I having a substitution of one or more amino acids selected from the group
25 consisting of Ala661, Thr664, Asn666 and Leu670. The invention also provides a polymerase mutant having one or more amino acid substitutions selected from the group consisting of Ala661Glu; Ala661Pro; Thr664Pro; Thr664Asn; Thr664Arg; Asn666Val; Thr664Pro and Val669Ile; Arg660Pro
30 and Leu670Thr; Arg660Trp and Thr664Lys; Ala664Gly and Thr664Asn; Ala661Gly and Asn666Ile; Ala661Pro and Asn666Ile; and Ala661Ser, Ala662Gly, Thr664Ser and Asn666Ile.

The invention also provides methods for the identification of one or more mutations in a gene using the high fidelity mutant DNA polymerases of the invention. For example, the use of a high fidelity
5 mutant to amplify a gene of interest gives greater confidence that the amplified sequence will more accurately reflect the actual sequence in the sample and minimizes the introduction of artifactual mutations during amplification of the gene. The higher accuracy of
10 gene amplification provided by a high fidelity mutant also improves the identification of genetic mutations due to the increased confidence that observed mutations are more likely to reflect genetic mutations in the sample rather than artifactual mutations introduced during
15 amplification.

Additionally, the invention provides methods for identifying one or more mutations in a gene by amplifying the gene using a high fidelity polymerase mutant under conditions which allow polymerase chain
20 reaction amplification. The gene is amplified by exposing the strands of the gene to repeated cycles of denaturing, annealing and elongation to produce an amplified gene product. Methods for amplifying genes using PCR are well known to those skilled in the art and
25 include those described previously in PCR Primer. A Laboratory Manual, Dieffenbach and Dveksler, eds., Cold Spring Harbor Press, Plainview, New York (1995). The presence or absence of one or more mutations in the gene can be determined by sequencing the amplified product
30 using methods well known to those skilled in the art.

The invention provides methods for accurately copying repetitive nucleotide sequences by amplifying the repetitive nucleotide sequence using a high fidelity

polymerase mutant. The repetitive nucleotide sequence can be in a gene or in a microsatellite between genes. The methods of amplifying the repetitive nucleotide sequences are carried out under conditions which allow
5 PCR amplification with repeated cycles of denaturing, annealing and elongation as described above.

The high fidelity mutants of the invention are advantageous for copying repetitive nucleotide sequences such as repetitive DNA because polymerases found in
10 nature undergo slippage when copying DNA containing repetitive sequences. Therefore when polymerases found in nature are used, the amplification products of a nucleotide sequence containing a repetitive sequence do not accurately reflect the size or sequence of a DNA
15 sequence in a sample. However, the use of a high fidelity polymerase mutant greatly increases the accuracy of an amplification product to reflect the actual size and sequence of the repetitive DNA sequence in the sample. Repetitive DNA can be found in microsatellites,
20 which contain multiple repetitive nucleotide sequences and are dispersed throughout the genome. These repetitive di-, tri- and tetranucleotides are frequently, but not invariably, located between genes.

The invention also provides a method for
25 determining an inherited mutation by amplifying a gene using a high fidelity polymerase mutant. Such an inherited mutation can be correlated with a genetic disease, thereby allowing diagnosis of the genetic disease. The invention additionally provides methods for
30 diagnosing a genetic disease by amplifying a gene using a high fidelity polymerase mutant. A genetic disease is one in which a disease is caused by a genetic mutation in a coding or non-coding region of DNA. Such a genetic

mutation can be a somatic mutation or a germline mutation. The methods of the invention can be used to diagnose any genetic disease using high fidelity polymerase mutants. Such genetic diseases can involve
5 point mutations, insertions and deletions.

The methods of the invention employ high fidelity polymerase mutants and can similarly be used to diagnose genetic diseases involving repetitive DNA. In one embodiment, the genetic disease involves mutations in
10 a microsatellite or repetitive DNA. Microsatellites are relatively stable in normal cells but are found to be unstable and to vary in length in some forms of hereditary and non-hereditary cancer, including hereditary nonpolyposis colorectal cancer (HNPCC), other
15 cancers that arise in HNPCC families, Muir-Torre syndrome and small-cell lung cancer (Loeb, Cancer Res. 54:5059-5063 (1994); Brentnall, Am. J. Pathol. 147:561-563 (1995); Honchel et al., Semin. Cell Biol. 6:45-52 (1995); Eshleman and Markowitz, Curr. Opin. Oncol. 7:83-89
20 (1995)). Microsatellite instability appears to be confined to tumors and is not present in normal tissues of affected individuals.

The accuracy of amplification products of repetitive DNA sequences provided by the high fidelity
25 mutants of the invention can be used to diagnose diseases involving mutations in repetitive DNA sequences. For example, with tumor samples, the accurate amplification of repetitive DNA sequences can be used to diagnose those cancers involving variable length in microsatellite DNA.
30 Since microsatellite instability appears to be confined to tumors, amplification of repetitive DNA using the high fidelity mutants of the invention can additionally be applied to determining the prognosis or extent of disease

- of a cancer patient, evaluating outcomes of therapy, staging tumors and determining tumor status. High fidelity mutants of the invention can also be applied to amplify DNA in blood samples to identify circulating
- 5 cells containing microsatellite instability as an indicator of a cancerous state.

- Other genetic diseases also involve repetitive DNA sequences, in particular, unstable triplet repeats. These unstable triplet repeat diseases involve increasing
- 10 lengths of triplet repeat regions, ranging from ~50 repeats in normal individuals, ~200 repeats in carriers to ~2000 repeats in affected individuals. Such unstable triplet repeat diseases include, for example, fragile X syndrome, spinal and bulbar muscular atrophy, myotonic
- 15 dystrophy, Huntington's disease, spinocerebellar ataxia type 1, fragile X E mild mental retardation and dentatorubral pallidoluysian atrophy (Monckton and Caskey, Circulation 91:513-520 (1995)). The diagnosis of unstable triplet repeat diseases is particularly valuable
- 20 since the onset of symptoms can occur later in some diseases and the severity of the symptoms of some diseases can be correlated with the size of the extended triplet repeat region. Thus, amplification of these triplet repeat regions to more accurately reflect the
- 25 actual size of the triplet repeat in the individual provides more accurate diagnosis and prognosis of the disease. Amplification of the large expanded regions associated with triplet repeat diseases can be carried out using low fidelity polymerase mutants of the
- 30 invention since low fidelity polymerase mutants would be more likely to copy through very long stretches of repetitive nucleotide sequences.

One method for identifying a genetic disease involves utilization of primers that hybridize to specific genes. The primers contain 3'-terminal nucleotides complementary to the corresponding nucleotide in the mutant but not to the wild type gene. The mismatched primer is used to extend the primer template in the presence of a high fidelity mutant polymerase. The presence of an extension product is indicative of a mutant gene.

The mismatch PCR method is based on the fact that a PCR primer that is not complementary to the template at the 3' end is an inefficient substrate for polymerases such as *Taq* DNA polymerase I. Wild type *Taq* DNA polymerase will occasionally misextend a mismatched primer, resulting in a false positive in an assay for a gene mutation. For example, a mutant gene with a rare TT mutation would be difficult to specifically amplify out of a pool of DNA molecules containing a wild type CC at the position of the TT mutant because wild type *Taq* DNA polymerase would occasionally misextend the wild type gene using the mismatched primer. In contrast, a high fidelity polymerase would not extend the mismatched primer. The products of a high fidelity polymerase in the mismatch PCR assay would therefore correspond to the mutant gene and would have fewer false positives than that observed with wild type *Taq* DNA polymerase. Thus, the more discriminating assay based on the use of high fidelity polymerases results in a better assay for detecting somatic mutations. The use of high fidelity mutants in such a mismatch-PCR based assay is disclosed herein (see Example V).

The invention also provides a method for randomly mutagenizing a gene by amplifying the gene using

the low fidelity polymerase mutants of the invention. The low fidelity polymerase mutants exhibit an efficiency of accurate base incorporation that is less than that of wild type polymerases. The efficiency of the low fidelity polymerase mutant is about 50% or more, generally 10% or more, and particularly 1% or more than that of a wild type polymerase. These low fidelity polymerase mutants would therefore exhibit between 2-fold to 100-fold lower fidelity than wild type polymerase.

10 The introduction of mutations into specific genes using low fidelity polymerase mutants of the invention is useful for determining the effects of mutations on the function of those gene products.

It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also included within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.

20

EXAMPLE I

Random Sequence Mutagenesis and Identification of Active Taq DNA Polymerase Mutants

This example demonstrates random nucleotide sequence mutagenesis of a polymerase target sequence and identification of active polymerase mutants.

Random sequence mutagenesis was used to introduce mutations into the O-helix of Taq DNA polymerase. Briefly, the Taq DNA polymerase I gene was obtained from the bacterial chromosome by cloning in

30 pKK223-3 (Pharmacia Biotech, Piscataway, NJ). A 3.2-kb

fragment containing the *Taq* DNA polymerase I gene, including the 5'-3' exonuclease domain and the *tac* promoter region, was further transferred into the *Sal*I site of pHSG576 (pTacTaq). The *Taq* DNA polymerase I gene was sequenced to confirm wild type sequence except for the lack of the N-terminal three amino acids.

A vector containing a nonfunctional insert within the *Taq* DNA polymerase I gene was constructed and subsequently replaced with an oligonucleotide containing the random sequence to avoid contamination with incompletely cut vectors. To generate the nonfunctional vector, a *Sac*II site was produced using site-directed mutagenesis by changing 2070C to G using a synthetic oligomer, 5'-GGG TCC ACG GCC TCC CGC GGG ACG CCG AAC ATC CAG CTG (SEQ ID NO:3) (*Sac*II-2) and the single-stranded plasmid pFC85 (Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985)). The *Bst*XI-*Nhe*I fragment that carries the *Sac*II site was substituted for the corresponding fragment in pTacTaq (pTacTaqSac). A *Sac*II-*Nhe*I fragment in pTacTaqSac was further replaced with the synthetic oligomer 5'-GGA CTG CAT ATG ACT G (SEQ ID NO:4) (DUM-U) hybridized with 5'-CTA GCA GTC ATA TGC AGT CCG C (SEQ ID NO:5) (DUM-D) to create the nonfunctional vector (Dube et al., Biochemistry 30:11760-11767 (1991)).

Oligonucleotides containing 9% random sequence, in which each nucleotide indicated in parentheses was 91% wild type nucleotide and 3% each of the other three nucleotides, were synthesized by Keystone Laboratories (Menlo Park, CA): O+9 RANDOM is 5'-CGG GAG GCC GTG GAC CCC CTG ATG (CGC CGG GCG GCC AAG ACC ATC AAC TTC GGG GTC CTC TAC) GGC ATG TCG GCC CAC CG (SEQ ID NO:6); O-0 RANDOM is 5'-TGG CTA GCT CCT GGG AGA GGC GGT GGG CCG ACA TGC C (SEQ ID NO:7). The 17 nucleotide sequences at the 3'

ends of the two oligonucleotides are complementary. Equimolar amounts of these oligonucleotides (20 pmol) were mixed, hybridized, and extended by five cycles of PCR reaction (94°C for 30 sec, 57°C for 30 sec, and 72°C for 30 sec) in a 100 µl reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 50 µM dNTPs, and 2.5 units of Taq DNA polymerase I. This PCR product (10 µl) was further amplified 25 cycles with 20 pmol of O(+)PRIMER (5'-TTC GGC GTC CCG CGG GAG GCC GTG GAC CCC CT) (SEQ ID NO:8) and 20 pmol of O(-)PRIMER (5'-GTA AGG GAT GGC TAG CTC CTG GGA) (SEQ ID NO:9) under the same conditions. The amplified product was purified by phenol/chloroform extraction followed by ethanol precipitation and digestion with the restriction enzymes, SacII and NheI, at 37°C for 30 min in 50 mM Tris-HCl (pH 7.9), 50 mM NaCl, 10 mM MgCl₂ and 1 mM dithiothreitol. The restriction fragment containing the random sequence was purified by phenol/chloroform extraction, ethanol precipitation, and filtration using a Microcon 30 filter (Amicon, Beverly, MA). For the totally random library, five oligonucleotides (80-mers), each having totally random sequence at one of the codons 659, 660, 663, 667 or 668, were combined in equal amounts and hybridized to O-0 RANDOM. After extension and digestion with endonucleases, the combined products were purified and processed as above.

A random library of Taq DNA polymerase genes containing randomized nucleotide sequence corresponding to the O-helix was generated by digesting the vector containing the nonfunctional insert with NheI and SacII restriction endonucleases. The large DNA fragment was isolated by electrophoresis in a 0.8% agarose gel and purified by using GenCleanII (Bio101, Vista, CA). This

large fragment, lacking the nonfunctional insert, was ligated with an oligonucleotide containing randomized sequence by incubating overnight at 16°C with T4 DNA ligase. The ligation mixture was then used to transform

5 DH5 α by electroporation according to Bio-Rad (Hercules, CA). After electroporation, 1 ml of SOC (2% bactotryptone/0.5% yeast extract/10 mM NaCl/2.5 mM KCl/10 mM MgCl₂/10 mM MgSO₄/20 mM glucose) was added and incubation continued for 1 h at 37°C. An aliquot was

10 plated on 2xYT (16 g/liter tryptone, 10 g/liter yeast extract, 5 g/liter NaCl, pH 7.3) containing 30 μ g/ml chloramphenicol to determine the total number of transformants, and the remainder was inoculated into 500 ml of 2xYT containing 30 μ g/ml chloramphenicol and

15 cultured at 37°C overnight. Plasmids (random library vector) were purified and used for transformation of *recA718 polA12* strain.

For genetic complementation to determine active polymerase mutants, *E. coli recA719 polA12* cells (SC18-12

20 *E. coli* B/r strain, which has the genotype *recA718 polA12 uvrA155 trpE65 lon-11 sulA1*) were transformed with plasmids pHSG576 or pTacTaq by electroporation (Bio-Rad Genepulser, 2kV, 25 μ FD, 400 Ω) (Sweasy and Loeb, *supra*, (1992); Sweasy and Loeb, Proc. Natl. Acad. Sci. USA

25 90:4626-4630 (1993); Witkin and Roegner-Maniscalco, J. Bacteriol. 174:4166-4168 (1992)). Thereafter, 1 ml of nutrient broth (NB) (8 g/liter) containing NaCl (4 g/liter) and 1 mM isopropyl β -D-thiogalactoside (IPTG) was added and the mixture was incubated for 1 h at 37°C.

30 The transformed cells were plated on nutrient agar plates (containing 23 g/liter Difco nutrient agar, 5 g/liter NaCl, 30 μ g/ml chloramphenicol, 12.5 μ g/ml tetracycline and 1 mM IPTG) and grown at 30°C overnight. Single colonies were transferred to NB for growth to logarithmic

phase at 30°C. Thereafter, ~10 µl (10⁴ cells) was introduced at the center of an agar plate, and the inoculation loop was gradually moved from the center to the periphery as the plate was rotated. Duplicate plates were incubated at 30°C or 37°C for 30 h. To determine complementation efficiency by Taq DNA polymerase I and to isolate mutants, cultures of the *recA718 polA12* strain harboring either pHSG576 or Taq DNA polymerase I were diluted with NB medium and plated (~500 colonies per plate). Duplicate plates were incubated at 30°C or 37°C, and visible colonies were counted after a 30 h incubation. Complementation was verified by a second round of electroporation and colony formation at the nonpermissive temperature. Cell-free extracts were prepared from selected colonies obtained at the restrictive temperature and assayed to confirm that they contained a temperature-resistant DNA polymerase activity (Lawyer et al., J. Biol. Chem. 264:6427-6437 (1989)).

Wild type Taq DNA polymerase I was tested for its ability to complement a temperature sensitive polymerase contained in the *E. coli* strain *recA718 polA12*, which is unable to grow at 37°C in rich media at low cell density (Witkin and Roegner-Maniscalco, 1992, *supra*). The temperature sensitive phenotype of *E. coli* strain *recA718 polA12* was complemented by transformation with the pTacTaq plasmid encoding wild type Taq DNA polymerase I as indicated by growth at 37°C. Therefore, this *E. coli* strain containing a temperature sensitive polymerase provides a good model system for testing Taq DNA polymerase I mutants.

To evaluate the involvement of different amino acid residues in catalysis by Taq DNA polymerase I,

random sequences were substituted for nucleotides encoding a portion of the substrate binding site of *Taq* DNA polymerase I (O-helix, amino acids Arg659 through Tyr671). The substituted stretch was 39 nucleotides long
5 with 9% randomization. At each position the proportion of the wild type residue was 91% and the other 3 nucleotides were present in equal amounts (3% each).

A library of 50,000 independent mutants was obtained. The number of colonies obtained at 37°C was
10 11.8% of that obtained at 30°C. Therefore, screening a randomized library using *E. coli* strain *recA718 polA12* provided approximately 5900 colonies containing active *Taq* DNA polymerase and potential polymerase mutants.

These results show that a randomized library
15 can be used to generate a population of polymerase mutants. These results also show the identification of active *Taq* DNA polymerase I mutants by screening for active polymerase mutants using genetic selection.

EXAMPLE II

20 Identification of *Taq* DNA Polymerase I Mutants and Immutable or Nearly Immutable Amino Acid Residues

This example describes the identification *Taq* DNA polymerase I mutants generated by a randomized library and the identification of immutable or nearly
25 immutable amino acid residues.

The active *Taq* DNA polymerase I mutants identified by the screen described in Example I were further characterized. The entire random nucleotide-containing insert was sequenced from a total of 234

plasmids obtained at 37°C (positively selected), 16 plasmids obtained at 30°C (nonselected) and 29 plasmids obtained at 30°C, which failed to grow at 37°C (negatively selected). All substitutions were in the randomized
5 nucleotides except for 12 clones.

Among the 230 positive plasmids, 168 contained silent mutations in one or more codons. At the amino acid level, 106 encoded the wild type residue and 124 encoded substitutions, in accord with the expected
10 distribution in the plasmid population. Of the 124 plasmids with amino acid changes, 40 were unique mutants obtained just once. The remaining 84 plasmids represented 21 different mutants. At least 79% of those encoding the same amino acid substitutions were
15 independently derived since they contained different silent mutations in other codons. In total, 61 different amino acid sequences were obtained that complemented the temperature-sensitive phenotype of the *recA718 polA12* host.

20 A compilation of the amino acid substitutions found in *Taq* DNA polymerase I is shown in Figure 2. Solid boxes indicate the amino acid residues for which no substitutions were detected. Dashed boxes mark the amino acid positions where only conservative substitutions were
25 found. The amino acid positions of *Taq* DNA polymerase I and corresponding positions of *E. coli* DNA polymerase I are indicated at the top. WT represents the wild type sequence and randomized amino acids are written in boldface type. The amino acids that have not been found
30 in the DNA polymerase I family are outlined (Braithwaite and Ito, Nucleic Acids Res. 21:787-802 (1993)). Panel A shows single mutations selected from the 9% library listed under the wild type amino acids. Panel B shows

the sequence of each multiply substituted mutant selected from the 9% library. Panel C shows mutations selected from the totally random library.

The distribution of single amino acid substitutions among the active mutants was not random (see Figure 2A). For example, numerous diverse substitutions were observed at Ala661 and Thr664. In contrast, no substitutions were detected at five positions (Arg659, Arg660, Lys663, Phe667 and Gly668). This uneven distribution of replacements is unlikely to be the result of a bias in the nucleotide composition of the random insert since sequencing of both the nonselected and negatively selected plasmids revealed multiple nucleotide substitutions at each of the targeted positions and because silent mutations were detected at each of these positions in the selected clones.

A nonrandom distribution of substitutions was also observed among active mutants containing multiple substitutions (see Figure 2B). Again, Ala661 and Thr664 were replaced with a variety of residues. However, no amino acid substitutions were observed in place of Arg659, Lys663 and Gly668, even though different silent nucleotide substitutions were found at each of these positions. A comparison of Figure 2A and B shows that substitutions at Arg660 and Phe667 occur only in the presence of substitutions at other positions. In addition to the mutants containing multiple substitutions shown in Figure 2B, two additional triple mutants were also found: mutant 44, with Ala661Pro, Thr664Arg, and Val669Leu; and mutant 54, with Ala661Thr, Thr664Pro and Ile665Val.

The partially substituted library (9%) does not provide a vigorous test of the immutability of specific codons. Only 0.07% of sequences at each codon would be expected to contain nucleotide substitutions at all three positions. To further probe the mutability of specific amino acid residues, a second library was constructed that contained totally random substitutions at a limited number of designated codons. In this library, nucleotides encoding each of the five amino acids Arg659, Arg660, Lys663, Phe667 and Gly668 were randomized. These were amino acid positions that did not yield single substitutions in the 9% random library (Figure 2A). Approximately 1300 transformants, which is 4 times more than the number required for each possible substitution at each of the target codons, were screened. At the nonpermissive temperature, 113 colonies were obtained, 84 of which contained codons that encoded the wild type amino acid sequence. Most of the amino acid substitutions occurred in place of Arg660 or Gly668.

Again, Arg659 and Lys663 were completely conserved, with 16 and 5 silent mutations scored at these codons, respectively. The expected number of silent mutations were 21 and 4.2, respectively, assuming that the 5 randomized oligomers that comprised the library were mixed in equimolar proportions. These numbers show that the oligomers were roughly equally represented in the library and that sufficient mutants were sampled to conclude that Arg659 and Lys663 are immutable in these genetic complementation experiments ($P < 0.05$ for Met and Trp, $P < 0.01$ for all other substitutions). Only Tyr substituted for Phe at position 667 (Figure 2C), and six silent mutations were scored for this codon. An additional mutant obtained with the totally randomized

library but not shown in Figure 2 is mutant 601, with double substitutions Ile665Asn and Val669Ile.

These results show that generating a random library and screening by genetic complementation provided
5 a number of active *Taq* DNA polymerase I mutants. These results also show that amino acid residues Arg659 and Lys663 were found to be immutable and Phe667 and Tyr671 were found to tolerate only conservative substitutions.

EXAMPLE III

10 Determination of the Fidelity of Active *Taq* DNA

Polymerase I Mutants

This example describes methods of determining the fidelity of active *Taq* DNA polymerase I mutants. Two types of assays are useful for determining the fidelity
15 of active polymerase mutants, a primer extension assay and a forward mutation assay.

Crude extracts were used to determine the fidelity of polymerase mutants. A single colony of *E. coli* DH5 α (F⁻, ϕ 80dlacZ Δ M15, Δ (lacZYA-argF)U169, *deoR*,
20 *recA1*, *endA1*, *phoA*, *hsdR17*(r_m⁻), *supE44*, λ^- , *thi-1*, *gyrA96*, *relA1*) carrying wild type or mutant *Taq* DNA polymerase I was inoculated into 40 ml of 2xYT (16 g/liter tryptone, 10 g/liter yeast extract, 5 g/liter NaCl, pH 7.3) containing 30 mg/liter chloramphenicol.
25 After incubation at 37°C overnight with vigorous shaking, an equal amount of fresh medium with 0.5 mM IPTG was added, and incubation was continued for 4 h. Cells were harvested, washed once with TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) and suspended in 100 μ l of buffer A
30 (50 mM Tris-HCl, pH 8.0, 2.4 mM phenylmethylsulfonyl

fluoride, 1 mM dithiothreitol, 0.5 mg/liter leupeptin, 1 mM EDTA, 250 mM KCl). Bacteria were lysed by incubating with lysozyme (0.2 mg/ml) at 0°C for 2 h. The lysate was centrifuged at 15,000 rpm (Sorvall, SA-600 rotor) (DuPont, Newtown, CT) for 15 min, and the supernatant solution was incubated at 72°C for 20 min. Insoluble material was removed by centrifugation.

Polymerases were purified as described previously with some modifications (Lawyer et al., PCR Methods Application 2:275-287 (1993)). Briefly, a single colony of *E. coli* DH5 α carrying wild type or mutant *Taq* DNA polymerase I was inoculated into 10 ml of 2xYT. Two ml of the inoculum was immediately added to each of 5 bottles containing 1 liter of 2xYT with 30 mg/liter chloramphenicol. After overnight incubation at 37°C with vigorous shaking, 1 liter of 2xYT containing 30 mg/liter chloramphenicol and 0.5 mM IPTG was added, and incubation was continued for 4 h. Cells were harvested, washed once with TE buffer and suspended in 100 ml buffer A. Bacteria were lysed by incubating with lysozyme (0.2 mg/ml) at 0°C for 2 h and then sonicating on ice for 45 sec by using a micro-tip probe (Sonifier, Branson Sonic Power, Danbury, CT).

The lysate was centrifuged at 15,000 rpm (Sorvall, SA-600 rotor) for 15 min, and the supernatant solution was incubated at 72°C for 20 min. Insoluble material was removed by centrifugation. Ammonium sulfate (0.2 M) and Polymin P (0.6%) were added and the suspension was held on ice for 1 h. After removal of the precipitate by centrifugation and filtration through a Costar 8310 filter, the filtrate was applied to a 3 x 8-cm phenyl-SEPHAROSE HP (Pharmacia Biotech) column equilibrated with buffer A containing 0.2 M ammonium

sulfate and 0.01% Triton X-100. The column was washed with the same buffer (300 ml) and activity was eluted with buffer B (TE buffer containing 0.01% Triton X-100 and 50 mM KCl). The eluate (100 ml) was dialyzed
5 overnight against 4 liters of buffer B and loaded onto a 0.8 x 8-cm heparin-SEPHAROSE CL6B (Pharmacia Biotech) column equilibrated with buffer B. After washing with buffer B (50 ml), activity was eluted in a 30 ml linear gradient of 50-500 mM KCl in TE buffer containing 0.01%
10 Triton X-100. Active fractions were collected, dialyzed against 50 mM Tris-HCl (pH 8.0) containing 50 mM KCl and 50% glycerol, and stored at -80°C.

To confirm and quantitate the presence of polymerase activity, crude extracts or purified enzyme
15 was incubated at 72°C for 5 min in 50 mM Tris-HCl (pH 8.0), 2 mM MgCl₂, 100 µM each dATP, dGTP, dCTP and dTTP, 0.2 µCi of (³H)dATP and 200 µg/ml activated calf thymus DNA. Incorporation of radioactivity into an acid-insoluble product was measured according to Battula and
20 Loeb (J. Biol. Chem. 249:4086-4093 (1974)). One unit represents incorporation of 10 nmol of dNMP in 1 h, corresponding to 0.1 unit as defined by Perkin-Elmer.

For the primer extension assay, the 14-mer primer 5'-CGCGCCGAATTCCC (SEQ ID NO:10) was ³²P-labeled at
25 the 5' end by incubation with (γ-³²P)ATP and T4 polynucleotide kinase and annealed to an equimolar amount of the template 46-mer
5'-GCGCGGAAGCTTGGCTGCAGAATATTGCTAGCGGGAATTCGGCGCG
(SEQ ID NO:11). Heat-inactivated *E. coli* extracts
30 containing 0.3-1 unit of wild type or mutant *Taq* DNA polymerases were incubated at 45°C for 60 min in 50 mM Tris-HCl (pH 8.0), 2 mM MgCl₂, 50 mM KCl, 20 µM each dATP, dGTP, dCTP and dTTP and 1.4 ng of the annealed template

primer. A set of four additional reactions, each lacking a different dNTP, was carried out for each polymerase. Purified enzyme (1 unit) was incubated for the times indicated under the same conditions as for crude
5 extracts. After electrophoresis in a 14% polyacrylamide gel containing 8M urea, reaction products were analyzed by autoradiography. Extension was quantified by using an NIH imaging program (see <http://www.nih.gov/>).

For the forward mutation assay, the non-coding
10 strand of the *lacZ α* gene contained in 200 ng of gapped M13mp2 DNA was copied by using 5 units of wild type or mutant *Taq* DNA polymerase I in a reaction mixture containing 50 mM Tris-HCl (pH 8.0), 2 mM MgCl₂ and 50 mM KCl (Feig et al. Proc. Natl. Acad. Sci. USA 91:6609-6613
15 (1994)). For determining low fidelity polymerase mutants, the reaction included 20 μ M each dNTP. For determining high fidelity polymerase mutants, the reaction was carried out with biased dNTP pools containing 0.5 mM of one dNTP and 20 mM of each of the
20 other three dNTPs. For example, the reaction could contain 0.5 mM dATP and 20 mM each of dGTP, dCTP and dTTP. After incubation at 72°C for 5 min, the DNA was transfected into host *E. coli* and the plaques were scored for white and pale blue mutant plaques (Tindall et al.,
25 Genetics 118:551-560 (1988)).

These results show that the fidelity of active *Taq* DNA polymerase mutants can be determined using a primer extension assay and a forward mutation assay.

EXAMPLE IVIdentification of Low Fidelity Taq DNA Polymerase I
Mutants

This example shows the identification of low
5 fidelity Taq DNA polymerase I mutants.

The active Taq DNA polymerase I mutants
identified in Example II were assayed by the methods
described in Example III to identify low fidelity
mutants. Screening for activity was carried out on 67 of
10 75 sequenced mutants, including all 38 with single amino
acid substitutions described in Figure 2. Plasmids
encoding the mutant polymerases were cloned, purified and
grown in *E. coli*, and host cells were analyzed for
expression of Taq DNA polymerase I by measuring the
15 activity of crude extracts. *E. coli* DNA polymerases and
nucleases were inactivated by heating at 72°C for 20 min.
The ability of heat-treated extracts to elongate primers
in the absence of a complete complement of four dNTPs was
then determined using a set of five reactions. One
20 reaction contained all four complementary nucleoside
triphosphates while each of the others lacked a different
dNTP ("minus conditions"). Elongation in the minus
reactions is limited by the rate of misincorporation at
template positions complementary to the missing dNTP.

25 A primer extension assay was performed on wild
type Taq DNA polymerase I and several mutants, revealing
that several mutants had elongation patterns that
differed from wild type Taq DNA polymerase. In the
presence of all four dNTPs, every extract examined
30 extended more than 90% of the hybridized primer to a
product of length similar to that of the template. In

the minus reactions, wild type *Taq* DNA polymerase I extended 48-60% of the primer up to, but not opposite, the first template position complementary to the missing dNTP. The remaining primer was terminated opposite the
5 missing dNTP, presumably by incorporation of a single non-complementary nucleotide, or was terminated further downstream, presumably by extension of the mispaired primer terminus. A variety of elongation patterns was observed for the 67 mutants. Thirteen mutants extended
10 more of the primer and/or synthesized a greater proportion of longer products than the wild type enzyme in three or four of the minus reactions. For example, mutant 2 formed full-length products in reactions lacking dGTP or dTTP. This increased extension presumably
15 reflects increased incorporation and/or extension of non-complementary nucleotides. Other mutants extended less of the primer or synthesized shorter products than the wild type enzyme, for example, mutant 5. In several cases, different amino acid substitutions at the same
20 position either increased or decreased extension in comparable minus reactions.

A compilation of amino acid replacements in the 13 mutants that displayed increased extension in at least three of the minus reactions is shown in Table I. With
25 the exception of Gly668, one or more substitutions that putatively reduce the accuracy of DNA synthesis were observed for each of the 9 non-conserved amino acids. Eleven mutants harbored substitutions at either Ala661 or Thr664, including several single mutants. This initial
30 screen with crude extracts suggested that a large number of changes are permitted in the O-helix that do not reduce the ability of *Taq* DNA polymerase I to complement the growth defect of *recA718 polA12*. Many of the

Table I. Low Fidelity Mutants of Taq DNA Polymerase I Identified in the Primer Extension Screen

		659			663			667			671			
WT :		R	R	A	A	K	T	I	N	F	G	V	L	Y
5														
	29 :			E										
	36 :						P					I		
	40 :			P										
	45 :						P							
10	53 :						N							
	130 :		P										T	
	156 :			S	G		S		I					
	175 :		W				K							
	206 :						R							
15	240 :				G		N							
	247 :			G					I					
	248 :								V					
	306 :			P					I					

substitutions in the O-helix that do not reduce the
 20 ability of Taq DNA polymerase I to carry out functional
 complementation reduce the fidelity of DNA synthesis in
 vitro.

To demonstrate that the reduction in fidelity
 exhibited by crude extracts is due to mutant Taq DNA
 25 polymerase I, wild type enzyme was purified as well as
 the three single mutants Ala661Glu, Ala661Pro and
 Thr664Arg. The mutant Ile665Thr, a mutant predicted to
 have no alteration in fidelity based on complementation
 assays, was also purified as a control. The mutated
 30 enzymes retained at least 29% of wild type activity in
 vitro, which is in accord with their ability to
 complement the growth defect caused in *E. coli* by

temperature-sensitive host DNA polymerase I and ensures that analysis of fidelity will not be complicated by major impairments of catalytic efficiency.

Primer extension assays were carried out with

5 the homogenous mutant polymerases. Wild type *Taq* DNA polymerase I extended most of the primer to one nucleotide before the template position opposite the missing complementary dNTP in a 5 min reaction. Only about 30% of the primers were elongated further. In

10 reactions containing equivalent activity, the mutant polymerases Ala661Glu, Thr664Arg and Ala661Pro extended a larger proportion of the primers past the sites where the wild type polymerase ceased synthesis. The control enzyme Ile665Thr yielded an elongation pattern similar to

15 that of the wild type enzyme. Elongation reactions with the three polymerases were also carried out for 60 min. Again, Ala661Glu and Thr664Arg synthesized a greater proportion of longer products than obtained with the wild type and Ile665Thr polymerases. Notably, Ala661Glu,

20 Thr664Arg and Ala661Pro synthesized longer products in 5 min than the wild type did in 60 min.

To further analyze the reduced fidelity exhibited by the low fidelity polymerase mutants, a time course of primer elongation was carried out. Wild type

25 *Taq* DNA polymerase I extended 9% of the primers past the first deoxyguanosine template residue within the 60 min incubation period, but elongation past the second deoxyguanosine was not detected. In the same interval, Thr664Arg extended 93% of the primer past the first

30 template deoxyguanosine, and elongation proceeded past as many as five template deoxyguanosines. Importantly, a comparable proportion of primers was extended at all time points, despite the striking difference in the length of

the products. These time course data indicate that greater elongation reflects increased ability to utilize non-complementary substrates and primer termini, rather than a putative difference in the amount of activity present.

In a forward mutation assay, the fidelity of DNA synthesis by the purified polymerases was quantitated by measuring the frequency of mutations produced by copying a biologically active template *in vitro* (Kunkel and Loeb, J. Biol. Chem 254:5718-5725 (1979)). The target sequence was the *lacZ α* gene located within a single-stranded region in gapped circular double-stranded M13mp2 DNA (Feig and Loeb, Biochemistry 32:4466-4473 (1993)). The gapped segment was filled by synthesis with the wild type or mutant enzymes. The double-stranded circular product was transfected into *E. coli*, and the mutation frequency was determined by scoring white and pale blue mutant plaques. A comparison of the specific activities and mutation frequencies of the purified enzymes is presented in Table II. After synthesis by wild type *Taq* DNA polymerase I, the mutation frequency was not greater than that of the uncopied control. Synthesis by Ala661Glu and Thr664Arg gave rise to mutation frequencies more than 7- and 25-fold greater, respectively, than that of the wild type polymerase.

A sample of independent, randomly chosen mutants produced by Thr664Arg was characterized by DNA sequence analysis using a THERMO SEQUENASE cycle sequencing kit (Amersham Life Science, Cleveland, OH). Both base substitutions and frameshifts were found

Table II. Mutation Frequency in the *lacZα* Forward Mutation Assay

5	Taq Pol I Specific Activity	<u>Plaques Scored</u>		Mutation Frequency
		Total	Mutant	
	units/mg			$\times 10^{-3}$
WT	66,000	8,637	22	2.5
A661E	45,000	6,782	116	17.1
T664R	23,000	5,148	324	62.9

10 throughout the targeted *lacZα* gene and its regulatory sequence. Of the 64 independent plaques, 57 had mutations in the target. Other mutations presumably occurred outside the target region. Some had more than one base substitution and a total of 66 mutations were

15 observed (see Figure 3). Among them, 61 were base substitutions. Transitions (38/61) were more frequent than transversions (23/61). T - C transitions accounted for 31 of 61 base substitutions, while T - A (9/61), A - T (8/61) and G - A (5/61) substitutions were less

20 frequent. This base substitution spectrum is essentially the same as that reported for wild type Taq DNA polymerase I (Tindall and Kunkel, *supra*, 1988). From these data, the base substitution fidelity of Thr664Arg can be calculated as 8.6×10^{-4} or 1 error per 1200

25 nucleotides. On the basis of the five frameshift mutants detected, the frameshift error can be calculated as 4.9×10^{-5} or 1 error per 20,000 nucleotides.

These results show that low fidelity Taq DNA polymerase I mutants were identified from a randomized

30 library using a genetic complementation screen. The fidelity of Taq DNA polymerase I mutants was determined by primer extension assays and forward mutation assays.

EXAMPLE VIdentification of High Fidelity Taq DNA Polymerase I
Mutants

This example shows the identification of high
5 fidelity Taq DNA polymerase I mutants.

The active Taq DNA polymerase I mutants
identified in Example II were assayed by the methods
described in Example III to identify high fidelity

Table III. Candidate High Fidelity Mutants of
10 Taq DNA Polymerase I

		659				663				667				671			
WT :		R	R	A	A	K	T	I	N	F	G	V	L	Y			
FL :													L				
15	74 :			E				T			L						
	146 :									D							
	147 :									I							
	149 :						I		D								
	169 :			S									L				
20	186 :							L									
	219 :					P	V	Y									
	254 :												V				
	407 :		Y														
	424 :									Y							
25	426 :		S														
	487 :											R					
	488 :		K														
	530 :											S					
	614 :											Q					

mutants. A panel of 75 active polymerases was screened. Candidate high fidelity polymerase mutants are shown in Table III.

Thirteen of the active polymerases exhibited greater
 5 accuracy in DNA synthesis. Table IV summarizes the results of a forward mutation assay of some of these high fidelity mutants. Several polymerase mutants displayed higher fidelity than the wild type *Taq* DNA polymerase. Polymerase mutants exhibiting particularly high fidelity
 10 are mutant 424, with Phe667Tyr, mutant 426, with Arg660Ser and mutant 488, with Arg660Lys.

Table IV. Fidelity of *Taq* DNA Polymerase Mutants in a *lacZ* Forward Mutation Assay

15	Enzyme	Total Plaques	Mutant Plaques	Mutation Frequency
				$\times 10^{-3}$
	Wild Type	5680	49	8.6
	High Fidelity Mutants			
20	MS147	7249	47	6.5
	MS169	7275	34	5.1
	MS254	6898	40	5.8
	MS424	4810	14	2.7
	MS426	5727	23	4.1
25	MS488	3442	13	1.5
	Low Fidelity Mutant			
	MS206	3333	133	40

These results show that Taq DNA polymerase mutants were identified and found to exhibit higher fidelity than wild type Taq DNA polymerase.

EXAMPLE VI

5 High Fidelity Taq DNA Polymerase Mutants Enhance the Sensitivity of Mismatch PCR-based Assays for Somatic Mutations

This example shows the use of high fidelity mutants obtained by mutating the active site O-helix of
10 Taq DNA polymerase I to enhance the sensitivity of mismatch PCR-based assays for somatic mutations.

Mismatch PCR is the basis of allele-specific identification of inherited mutations within genes and somatic mutations that occur in tumors. In these
15 studies, one compares the extension of a correctly matched primer with the lack of extension using a primer with a 3'-terminal mismatch. The rate of extension by DNA polymerase using a primer with a single mismatch compared to a primer with a 3'-complementary base pair
20 (matched) terminus is approximately 10^{-5} (Perinno and Loeb, J. Biol. Chem. 262:2898-2905 (1989)). Elongation from a double mismatch is even less frequent, and thus offers an even more stringent test of the inability of mutant Taq DNA polymerases to elongate a mismatched
25 primer terminus.

A template containing the wild type sequence of human DNA polymerase- β at nucleotide positions 886-889 (CCCCTGGG) was utilized. PCR reactions were carried out with two complementary primers that flank the sequence
30 (matched) or with one matched template and a second

mismatched template containing a terminally mismatched primer with AA at the 3' terminal position. The AA would be across from the CC (underlined) in the template strand. In these studies, the ratio of templates containing the complementary and non-complementary sequences were varied. The PCR amplified product was separated by polyacrylamide gel electrophoresis and quantitated by phosphoimage analysis. Wild type *Taq* DNA polymerase detected one molecule of template containing a TT substitution in place of the two template CC when present in a population of 10^5 molecules containing the non-mutant templates with the CC substitution. In contrast, both of the high fidelity *Taq* DNA polymerase mutants, with substitutions Phe667Tyr and Arg659Ser, detected one molecule of the TT template amongst 10^8 molecules of the CC template when the primer contained two terminal 3'-AA nucleotide residues.

These results show that high fidelity *Taq* DNA polymerase mutants have two to three orders of magnitude enhanced sensitivity for detecting mutant DNA using a mismatch PCR-based assay.

EXAMPLE VII

High Fidelity *Taq* DNA Polymerase Mutants Enhance Sensitivity of Detection of Repetitive DNA Sequences

This example demonstrates the use of high fidelity polymerase mutants to enhance the sensitivity and accuracy of amplifying repetitive DNA sequences.

Detection of the length of unstable microsatellite DNA in certain human tumors has depended on PCR amplification of specific sequences and determination of changes in electrophoretic mobility in

gels. Due to the slippage of DNA polymerase while copying repetitive DNA, the interpretation of the results of this method have remained unsatisfactory.

High fidelity *Taq* DNA polymerases are
5 identified using the methods described in Examples I and III. DNA templates containing runs of CA repeats with the number of repeats varying from 5 to 50 are used to test high fidelity *Taq* DNA polymerase mutants. After 20 to 70 rounds of PCR amplification, the product of the
10 reaction is displayed on polyacrylamide gels. High fidelity polymerase mutants which display less slippage errors copying the repetitive sequences are identified. These high fidelity polymerase mutants are used to amplify repetitive DNA sequences in samples, for example
15 tissue or tumor samples.

These results show that high fidelity mutants having enhanced sensitivity and accuracy in amplifying repetitive DNA sequences can be identified and used to amplify repetitive DNA in tissue or tumor samples.

20 Throughout this application various publications have been referenced. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this
25 invention pertains.

Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the
30 invention. It should be understood that various

modifications can be made without departing from the spirit of the invention.

We claim:

1. A method for identifying a thermostable polymerase having altered fidelity, comprising generating a random population of polymerase mutants by mutating one
5 or more amino acid residues adjacent to an immutable or nearly immutable residue in an active site O-helix of a thermostable polymerase and screening said population for one or more active polymerase mutants.
2. The method of claim 1, further comprising
10 determining a fidelity of said active polymerase mutant.
3. The method of claim 1, wherein said one or more amino acid residues is immediately adjacent to an immutable or nearly immutable residue.
4. The method of claim 1, wherein said one or
15 more amino acid residues is adjacent to an amino acid residue corresponding to Arg659, Lys663, Phe667 or Tyr671 in *Taq* DNA polymerase.
5. The method of claim 4, wherein said thermostable polymerase is *Taq* DNA polymerase.
- 20 6. An isolated thermostable polymerase mutant having altered fidelity, wherein said polymerase mutant comprises one or more mutated amino acid residues adjacent to an immutable or nearly immutable residue in the active site O-helix of a thermostable polymerase.
- 25 7. The polymerase mutant of claim 6, wherein said polymerase is *Taq* DNA polymerase.

8. The polymerase mutant of claim 6, wherein said one or more amino acid residues is immediately adjacent to an immutable or nearly immutable residue.

9. The polymerase mutant of claim 6, wherein
5 said mutated amino acid residue is adjacent to an amino acid residue corresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNA polymerase.

10. The polymerase mutant of claim 9, wherein said polymerase is Taq DNA polymerase.

10 11. The polymerase mutant of claim 7, wherein said mutant is a high fidelity mutant.

12. The polymerase mutant of claim 11, wherein said polymerase mutant comprises one or more amino acid substitutions selected from the group consisting of
15 Arg660Tyr; Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; and Gly668Gln.

13. The polymerase mutant of claim 7, wherein said mutant is a low fidelity mutant.

14. The polymerase mutant of claim 13, wherein
20 said polymerase mutant comprises substitution of one or more amino acids selected from the group consisting of Ala661, Thr664, Asn666 and Leu670.

15. An isolated nucleic acid molecule encoding a polymerase mutant having high fidelity, comprising a
25 nucleotide sequence encoding substantially an amino acid sequence of Taq DNA polymerase I comprising one or more amino acid substitutions selected from the group

consisting of Arg660Tyr; Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; and Gly668Gln.

16. An isolated nucleic acid molecule encoding a polymerase mutant having low fidelity, comprising a nucleotide sequence encoding substantially an amino acid sequence of Taq DNA polymerase I comprising substitution of one or more amino acids selected from the group consisting of Ala661, Thr664, Asn666 and Leu670.

17. A method for identifying one or more mutations in a gene, comprising amplifying said gene using a high fidelity polymerase mutant under conditions which allow polymerase chain reaction amplification.

18. A method for identifying one or more mutations in a gene, comprising amplifying said gene using the high fidelity polymerase mutant of claim 11 under conditions which allow polymerase chain reaction amplification.

19. The method of claim 17, wherein said gene is amplified by exposing the strands of said gene to repeated cycles of denaturing, annealing and elongation to produce an amplified product.

20. The method of claim 19, further comprising determining the presence or absence of one or more mutations in the sequence of said gene.

21. The method of claim 17, wherein said polymerase mutant comprises one or more amino acid substitutions selected from the group consisting of Arg660Tyr; Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; and Gly668Gln.

22. A method for accurately copying repetitive nucleotide sequences, comprising amplifying said repetitive nucleotide sequence using a high fidelity polymerase mutant.

5 23. The method of claim 22, wherein said repetitive nucleotide sequence is in a gene.

24. The method of claim 22, wherein said repetitive nucleotide sequence is in a microsatellite between genes.

10 25. A method for accurately copying repetitive nucleotide sequences, comprising amplifying said repetitive nucleotide sequence using said high fidelity polymerase mutant of claim 11.

15 26. A method for determining an inherited mutation, comprising amplifying a gene using a high fidelity polymerase mutant.

27. A method for diagnosing a genetic disease, comprising correlating the inherited mutation determined in claim 26 with said genetic disease.

20 28. A method for diagnosing a genetic disease, comprising amplifying a gene using a high fidelity polymerase mutant.

25 29. A method for diagnosing a genetic disease, comprising amplifying a gene using said high fidelity polymerase mutant of claim 11.

30. The method of claim 28, wherein said genetic disease comprises mutations in microsatellite or repetitive DNA.

31. The method of claim 30, wherein said
5 genetic disease is cancer.

32. A method for determining the prognosis of a genetic disease, comprising amplifying said gene in claim 28.

33. The method of claim 28, wherein said
10 polymerase mutant comprises one or more amino acid substitutions selected from the group consisting of Arg660Tyr; Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; and Gly668Gln.

34. A method for randomly mutagenizing a gene,
15 comprising amplifying said gene using a low fidelity polymerase mutant.

35. A method for randomly mutagenizing a gene, comprising amplifying said gene using said low fidelity polymerase mutant of claim 13.

20 36. The method of claim 35, wherein said polymerase mutant comprises substitution of one or more amino acid residues selected from the group consisting of Ala661, Thr664, Asn666 and Leu670.

1 / 7

AAGCTCAGAT CTACCTGCGCT GAGGGCGTCC GGTTCAGCT GGCCCTTCCC GAGGGGGAGA	60
GGGAGGCGTT TCTAAAAGCC CTTACAGACG CTACCCGGGG GCGGGTG6TG GAAGGGTAAC	120
ATG AGG GGG ATG CTG CCC CTC TTT GAG CCC AAG GGC CGG GTC CTC CTG Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu	168
GTG GAC GGC CAC CAC CTG GCC TAC CGC ACC TTC CAC GCC CTG AAG GGC Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly	216
CTC ACC ACC AGC CGG GGG GAG CCG GTG CAG GCG GTC TAC GGC TTC GCC Leu Thr Ser Arg Gly Glu Val Gln Ala Val Gly Phe Ala	264
AAG AGC CTC CTC AAG GCC CTC AAG GAG GAC GGG GAC GCG GTG ATC GTG Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val	312
GTC TTT GAC GCC AAG GCC CTC TCC TTC CGC CAC GAG GCC TAC GGG GGG Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly	360
TAC AAG GCG GGC CGG GCC CCC ACG CCG GAG GAC TTT CCC CGG CAA CTC Tyr Lys Ala Gly Arg Ala Pro Thr Pro Asp Phe Pro Arg Gln Leu	408
GCC CTC ATC AAG GAG CTG GTG GAC CTC CTG GGG CTG GCG CGC CTC GAG Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu	456
GTC CCG GGC TAC GAG GCG GAC GAC GTC CTG GCC AGC CTG GCC AAG AAG Val Pro Gly Tyr Glu Ala Asp Val Leu Ala Ser Leu Ala Lys Lys	504
GCG GAA AAG GAG GGC TAC GAG GTC CGC ATC CTC ACC GCC GAC AAA GAC Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp	552
CTT TAC CAG CTC CTT TCC GAC CGC ATC CAC GTC CTC CAC CCC GAG GGG Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly	600
TAC CTC ATC ACC CCG GCC TGG CTT TGG GAA AAG TAC GGC CTG AGG CCC Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro	648
GAC CAG TGG GCC GAC TAC CCG GCC CTG ACC GGG GAC GAG TCC GAC AAC Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn	696
CTT CCC GGG GTC AAG GGC ATC GGG GAG AAG ACG GCG AGG AAG CTT CTG Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu	744

FIG. 1A

2 / 7

GAG Glu	GAG Glu	TGG Trp	GGG Gly	AGC Ser	CTG Leu	GAA Glu	GCC Ala	CTC Leu	CTC Leu	AAG Lys	AAC Asn	CTG Leu	GAC Asp	CGG Arg	CTG Leu	792
210						215				220						
AAG Lys	CCC Pro	GCC Ala	ATC Ile	CGG Arg	GAG Glu	AAG Lys	ATC Ile	CTG Leu	GCC Ala	CAC His	ATG Met	GAC Asp	GAT Asp	CTG Leu	AAG Lys	840
225					230					235					240	
CTC Leu	TCC Ser	TGG Trp	GAC Asp	CTG Leu	GCC Ala	AAG Lys	GTG Val	CGC Arg	ACC Thr	GAC Asp	CTG Leu	CCC Pro	CTG Leu	GAG Glu	GTG Val	888
				245					250					255		
GAC Asp	TTC Phe	GCC Ala	AAA Lys	AGG Arg	CGG Arg	GAG Glu	CCC Pro	GAC Asp	CGG Arg	GAG Glu	AGG Arg	CTT Leu	AGG Arg	GCC Ala	TTT Phe	936
			260					265					270			
CTG Leu	GAG Glu	AGG Arg	CTT Leu	GAG Glu	TTT Phe	GGC Gly	AGC Ser	CTC Leu	CTC Leu	CAC His	GAG Glu	TTC Phe	GGC Glu	CTT Leu	CTG Leu	984
		275					280					285				
GAA Glu	AGC Ser	CCC Pro	AAG Lys	GCC Ala	CTG Leu	GAG Glu	GAG Glu	GCC Ala	CCC Pro	TGG Trp	CCC Pro	CCG Pro	CCG Pro	GAA Glu	GGG Gly	1032
		290				295					300					
GCC Ala	TTC Phe	GTG Val	GGC Gly	TTT Phe	GTG Val	CTT Leu	TCC Ser	CGC Arg	AAG Lys	GAG Glu	CCC Pro	ATG Met	TGG Trp	GCC Ala	GAT Asp	1080
305					310					315					320	
CTT Leu	CTG Leu	GCC Ala	CTG Leu	GCC Ala	GCC Ala	AGG Arg	GGG Gly	GGC Gly	CGG Arg	GTC Val	CAC His	CGG Arg	GCC Ala	CCC Pro		1128
				325				330					335			
GAG Glu	CCT Pro	TAT Tyr	AAA Lys	GCC Ala	CTC Leu	AGG Arg	GAC Asp	CTG Leu	AAG Lys	GAG Glu	GCG Ala	CGG Arg	GGG Gly	CTT Leu	CTC Leu	1176
			340					345					350			
GCC Ala	AAA Lys	GAC Asp	CTG Leu	AGC Ser	GTT Val	CTG Leu	GCC Ala	CTG Leu	AGG Arg	GAA Glu	GGC Gly	CTT Leu	GGC Gly	CTC Leu	CCG Pro	1224
		355					360					365				
CCC Pro	GGC Gly	GAC Asp	GAC Asp	CCC Pro	ATG Met	CTC Leu	CTC Leu	GCC Ala	TAC Tyr	CTC Leu	CTG Leu	GAC Asp	CCT Pro	TCC Ser	AAC Asn	1272
		370				375					380					
ACC Thr	ACC Thr	CCC Pro	GAG Glu	GGG Gly	GTG Val	GCC Ala	CGG Arg	CGC Arg	TAC Tyr	GGC Gly	GGG Gly	GAG Glu	TGG Trp	ACG Thr	GAG Glu	1320
					390					395					400	
GAG Glu	GGC Ala	GGG Gly	GAG Glu	CGG Arg	GCC Ala	CTT Leu	TCC Ser	GAG Glu	AGG Arg	CTC Leu	TTC Phe	GCC Ala	AAC Asn	CTG Leu		1368
				405				410				415				
TGG Trp	GGG Gly	AGG Arg	CTT Leu	GAG Glu	GGG Gly	GAG Glu	GAG Glu	AGG Arg	CTC Leu	CTT Leu	TGG Trp	CTT Leu	TAC Tyr	CGG Arg	GAG Glu	1416
			420					425					430			

FIG. 1B

3 / 7

GTG Val	GAG Glu	AGG Arg 435	CCC Pro	CTT Leu	TCC Ser	GCT Ala	GTC Val 440	CTG Leu	GCC Ala	CAC His	ATG Met	GAG Glu 445	GCC Ala	ACG Thr	GGG Gly	1464
GTG Val	CGC Arg 450	CTG Leu	GAC Asp	GTG Val	GCC Ala	TAT Tyr 455	CTC Leu	AGG Arg	GCC Ala	TTG Leu	TCC Ser 460	CTG Leu	GAG Glu	GTG Val	GCC Ala	1512
GAG Glu 465	GAG Glu	ATC Ile	GCC Ala	CGC Arg	CTC Leu 470	GAG Glu	GCC Ala	GAG Glu	GTC Val	TTC Phe 475	CGC Arg	CTG Leu	GCC Ala	GGC Gly	CAC His 480	1560
CCC Pro	TTC Phe	AAC Asn	CTC Leu	AAC Asn 485	TCC Ser	CGG Arg	GAC Asp	CAG Gln	CTG Leu 490	GAA Glu	AGG Arg	GTC Val	CTC Leu	TTT Phe 495	GAC Asp	1608
GAG Glu	CTA Leu	GGG Gly	CTT Leu 500	CCC Pro	GCC Ala	ATC Ile	GGC Gly	AAG Lys 505	ACG Thr	GAG Glu	AAG Lys	ACC Thr	GGC Gly 510	AAG Lys	CGC Arg	1656
TCC Ser	ACC Thr	AGC Ser 515	GCC Ala	GCC Ala	GTC Val	CTG Leu	GAG Glu 520	GCC Ala	CTC Leu	CGC Arg	GAG Glu	GCC Ala 525	CAC His	CCC Pro	ATC Ile	1704
GTG Val	GAG Glu	AAG Lys 530	ATC Ile	CTG Leu	CAG Gln	TAC Tyr 535	CGG Arg	GAG Glu	CTC Leu	ACC Thr	AAG Lys 540	CTG Leu	AAG Lys	AGC Ser	ACC Thr	1752
TAC Tyr 545	ATT Ile	GAC Asp	CCC Pro	TTG Leu	CCG Pro 550	GAC Asp	CTC Leu	ATC Ile	CAC His	CCC Pro 555	AGG Arg	ACG Thr	GGC Gly	CGC Arg	CTC Leu 560	1800
CAC His	ACC Thr	CGC Arg	TTC Phe	AAC Asn 565	CAG Gln	ACG Thr	GCC Ala	ACG Thr	GCC Ala 570	ACG Thr	GGC Gly	AGG Arg	CTA Leu	AGT Ser 575	AGC Ser	1848
TCC Ser	GAT Asp	CCC Pro	AAC Asn 580	CTC Leu	CAG Gln	AAC Asn	ATC Ile	CCC Pro 585	GTC Val	CGC Arg	ACC Thr	CCG Pro	CTT Leu 590	GGG Gly	CAG Gln	1896
AGG Arg	ATC Ile	CGC Arg 595	CGG Arg	GCC Ala	TTC Phe	ATC Ile	GCC Ala 600	GAG Glu	GAG Glu	GGG Gly	TGG Trp	CTA Leu 605	TTG Leu	GTG Val	GCC Ala	1944
CTG Leu	GAC Asp 610	TAT Tyr	AGC Ser	CAG Gln	ATA Ile	GAG Glu 615	CTC Leu	AGG Arg	GTG Val	CTG Leu	GCC Ala 620	CAC His	CTC Leu	TCC Ser	GGC Gly	1992
GAC Asp 625	GAG Glu	AAC Asn	CTG Leu	ATC Ile	CGG Arg 630	GTC Val	TTC Phe	CAG Gln	GAG Glu	GGG Gly 635	CGG Arg	GAC Asp	ATC Ile	CAC His	ACG Thr 640	2040
GAG Glu	ACC Thr	GCC Ala	AGC Ser	TGG Trp 645	ATG Met	TTC Phe	GGC Gly	GTC Val	CCC Pro 650	CGG Arg	GAG Glu	GCC Ala	GTG Val	GAC Asp 655	CCC Pro	2088

FIG. 1C

4 / 7

CTG Leu	ATG Met	CGC Arg	CGG Arg 660	GCG Ala	GCC Ala	AAG Lys	ACC Thr	ATC Ile 665	AAC Asn	TTC Phe	GGG Gly	GTC Val	CTC Leu 670	TAC Tyr	GGC Gly	2136
ATG Met	TCG Ser	GCC Ala 675	CAC His	CGC Arg	CTC Leu	TCC Ser	CAG Gln 680	GAG Glu	CTA Leu	GCC Ala	ATC Ile	CCT Pro 685	TAC Tyr	GAG Glu	GAG Glu	2184
GCC Ala 690	CAG Gln	GCC Ala	TTC Phe	ATT Ile	GAG Glu	CGC Arg 695	TAC Tyr	TTT Phe	CAG Gln	AGC Ser	TTC Phe 700	CCC Pro	AAG Lys	GTG Val	CGG Arg	2232
GCC Ala 705	TGG Trp	ATT Ile	GAG Glu	AAG Lys	ACC Thr 710	CTG Leu	GAG Glu	GAG Glu	GGC Gly	AGG Arg 715	AGG Arg	CGG Arg	GGG Gly	TAC Tyr 720	GTG Val	2280
GAG Glu	ACC Thr	CTC Leu	TTC Phe	GGC Gly 725	CGC Arg	CGC Arg	CGC Arg	TAC Tyr	GTG Val 730	CCA Pro	GAC Asp	CTA Leu	GAG Glu	GCC Ala 735	CGG Arg	2328
GTG Val	AAG Lys	AGC Ser	GTG Val 740	CGG Arg	GAG Glu	GCG Ala	GCC Ala	GAG Glu 745	CGC Arg	ATG Met	GCC Ala	TTC Phe	AAC Asn 750	ATG Met	CCC Pro	2376
GTC Val	CAG Gln	GGC Gly 755	ACC Thr	GCC Ala	GCC Ala	GAC Asp	CTC Leu 760	ATG Met	AAG Lys	CTG Leu	GCT Ala	ATG Met 765	GTG Val	AAG Lys	CTC Leu	2424
TTC Phe 770	CCC Pro	AGG Arg	CTG Leu	GAG Glu	GAA Glu	ATG Met 775	GGG Gly	GCC Ala	AGG Arg	ATG Met	CTC Leu 780	CTT Leu	CAG Gln	GTC Val	CAC His	2472
GAC Asp 785	GAG Glu	CTG Leu	GTC Val	CTC Leu	GAG Glu 790	GCC Ala	CCA Pro	AAA Lys	GAG Glu	AGG Arg 795	GCG Ala	GAG Glu	GCC Ala	GTG Val	GCC Ala 800	2520
CGG Arg	CTG Leu	GCC Ala	AAG Lys 805	GAG Glu	GTC Val	ATG Met	GAG Glu	GGG Gly	GTG Val 810	TAT Tyr	CCC Pro	CTG Leu	GCC Ala 815	GTG Val	CCC Pro	2568
CTG Leu	GAG Glu	GTG Val	GAG Glu 820	GTG Val	GGG Gly	ATA Ile	GGG Gly	GAG Glu 825	GAC Asp	TGG Trp	CTC Leu	TCC Ser	GCC Ala 830	AAG Lys	GAG Glu	2616
TGATACCACC																2626

FIG. 1D

5 / 7




FIG. 2A




FIG. 2C

6/7

Taq E.coli	659 754				663 758			667 762		671 766			
WT :	R	R	A	A	K	T	I	N	F	G	V	L	Y
24 :						P					I	F	
36 :			S	S		S	V						
42 :			E			A							
65 :			R			S							
73 :			T			R							
75 :			P			L							
109 :				S							I		
117 :				S							T		F
122 :			R										
123 :													
126 :													
129 :	P												
130 :													
149 :						I		D					
151 :						R		I					
152 :			S			S							
169 :						K					L		
175 :	W					P		I					
184 :						S							
213 :	W					N							
228 :						T							
240 :				G									
247 :			G			S		I					
252 :			E			I							
272 :			P			N							
280 :			P			R							
306 :						P							
307 :						S							
308 :			P										
44 :			T										
54 :			E										
74 :			G										
110 :			P										
219 :													
250 :	Q												
30 :			S	G									
156 :													

FIG. 2B

7/7




FIG. 3



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/12, 15/10, 15/54 // C12Q 1/68	A3	(11) International Publication Number: WO 98/23733 (43) International Publication Date: 4 June 1998 (04.06.98)
<p>(21) International Application Number: PCT/US97/21940</p> <p>(22) International Filing Date: 26 November 1997 (26.11.97)</p> <p>(30) Priority Data: 60/031,496 27 November 1996 (27.11.96) US</p> <p>(71) Applicant: UNIVERSITY OF WASHINGTON [US/US]; Suite 200, 1107 N.E. 45th, Seattle, WA 98105 (US).</p> <p>(72) Inventors: LOEB, Lawrence, A.; 13808 Northeast 36th Place, Bellevue, WA 98005 (US). HOOD, Leroy; 6411 N.E. Windermere Road, Seattle, WA 98105 (US). SUZUKI, Motoshi; Aban Rafure Shiga 7-902, Shiga-cho, Kita-ku, Nogyo 462 (JP).</p> <p>(74) Agents: GAY, David, A. et al.; Campbell & Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).</p>	<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 16 July 1998 (16.07.98)</p>	
<p>(54) Title: THERMOSTABLE POLYMERASES HAVING ALTERED FIDELITY</p> <p>(57) Abstract</p> <p>The present invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example, the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	ML	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MK		TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 97/21940

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N9/12 C12N15/10 C12N15/54 //C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M. SUZUKI ET AL., : "Random mutagenesis of <i>Thermus aquaticus</i> DNA polymerase I: Concordance of immutable sites in vivo with the crystal structure" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 93, 1 September 1996, WASHINGTON, DC, US, pages 9670-9675, XP002062865	1-11
Y	see the whole document	17-32, 34-36
Y	EP 0 416 801 A (IMPERIAL CHEMICAL INDUSTRIES PLC) 13 March 1991 see page 4, line 34-37 see page 5, line 49 - page 6, line 46 see page 11, line 10-55 --- -/-	17-32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

7 May 1998

Date of mailing of the international search report

02.06.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3018

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

Intern 1al Application No

PCT/US 97/21940

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 02090 A (PROMEGA CORP) 21 February 1991 see page 9-10 ---	34-36
A	WO 96 10640 A (LIFE TECHNOLOGIES INC) 11 April 1996 see the whole document ---	1,2,6
A	WO 95 14782 A (OREGON STATE) 1 June 1995 see abstract; examples 1-9 ---	1,2,5,7, 10,11,18
A	S.TABOR AND C.C. RICHARDSON: "A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy and dideoxyribonucleotides" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, WASHINGTON, DC, US, pages 6339-6343, XP000606203 cited in the application see the whole document ---	1-5
A	WO 96 34980 A (RHONE POULENC RORER SA) 7 November 1996 see page 6, line 21 - page 8, line 3 ---	22-25,30
A	L.A. LOEB: "Microsatellite instability: Marker of a mutator phenotype in cancer" CANCER RESEARCH, vol. 54, 1994, PHILADELPHIA, PA, US, pages 5059-5063, XP002064237 cited in the application see the whole document ---	30,31
A	EP 0 727 496 A (HARVARD COLLEGE) 21 August 1996 see page 6, line 45-50 see page 8, line 39-49; examples 1,2,6 ---	34-36
P,X	M. SUZUKI ET AL., : "Low fidelity mutants in the O-helix of Thermus aquaticus DNA polymerase I" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 17, 25 April 1997, BETHESDA, MD, US, pages 11228-11235, XP002062866 see the whole document --- -/--	13,14, 16,18, 34-36

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/21940

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>T.G. NEWCOMB ET AL., : "High fidelity Taq polymerases for mutation detection" FASEB JOURNAL, vol. 11, no. 9, 24 August 1997, BETHESDA, MD, US, page A1249 XP002062867 see the whole document -----</p>	<p>1-11, 17-20, 26,31</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/21940

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0416801 A	13-03-91	AT 145249 T	15-11-96
		AU 649229 B	19-05-94
		AU 6212790 A	14-03-91
		CA 2024769 A	08-03-91
		DE 69029113 D	19-12-96
		DE 69029113 T	07-08-97
		GB 2235769 A,B	13-03-91
		IE 64396 B	09-08-95
WO 9102090 A	21-02-91	US 5108892 A	28-04-92
		AU 6341190 A	11-03-91
WO 9610640 A	11-04-96	CA 2174944 A	11-04-96
		EP 0725827 A	14-08-96
		JP 9506783 T	08-07-97
WO 9514782 A	01-06-95	US 5474920 A	12-12-95
		AU 1101595 A	13-06-95
WO 9634980 A	07-11-96	FR 2733766 A	08-11-96
		AU 5767896 A	21-11-96
		CZ 9703467 A	14-01-98
		EP 0826068 A	04-03-98
		NO 974974 A	28-10-97
EP 0727496 A	21-08-96	US 5614365 A	25-03-97
		DE 29513622 U	19-10-95
		DE 29513639 U	19-10-95
		JP 2691149 B	17-12-97
		JP 8205874 A	13-08-96
		AT 143057 T	15-10-96
		AU 4193396 A	06-05-96
		CA 2201885 A	25-04-96
		DE 69400567 D	24-10-96
		DE 69400567 T	06-02-97
		DE 655506 T	28-09-95
		EP 0655506 A	31-05-95
		ES 2072238 T	16-07-95
		FI 971611 A	13-06-97
		HU 77037 A	02-03-98

Information on patent family members

PCT/US 97/21940

Form PCT/ISA/210 (patent family annex) (July 1992)